Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2833-2843

  Vuong, Le T ^a   Ruckle, Jon L ^b   Blood, Arlin B ^b,c   Reid, Michael J ^d   Wasnich, Richard D ^b   Synal, Hans Arno ^e   Dueker, Stephen R ^a  

^a Vitalea Science   (United States)

^b Covance Clinical Research Unit ^*  (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Freeland Pharma Consulting   (United States)

^e ETH ZURICH   (Switzerland)

Author keywords

Absorption; Accelerator mass spectrometry; AMS; AZT; Cell loading; Human; Isotope; Kinetics; Leukocytes; Microdose; Microdosing; Pharmacokinetics; ZDV

Indexed keywords

CARBON 14; ZIDOVUDINE;

ADULT; ARTICLE; BINDING SITE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FECES ANALYSIS; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; SALIVA ANALYSIS; URINALYSIS;

EID: 49449110661     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21160     Document Type: Article

References (22)

1. Vogel JS. 2005. Accelerator mass spectrometry for quantitative in vivo tracing. Biotechniques Jun; Suppl:25-29.
2. Vogel JS, Turteltaub KW, Finkel K, Nelson DE. 1995. Accelerator mass spectrometry. Anal Chem 67:353A-359A.
3. Brown K, Dingley KH, Turteltaub KW. 2005. Accelerator mass spectrometry for biomedical research. Methods Enzymol 402:423-443.
4. Dueker SR, Lin Y, Buchholz BA, Schneider PD, Lame MW, Segall HJ, Vogel JS, Clifford AJ. 2000. Long-term kinetic study of beta-carotene, using accelerator mass spectrometry in an adult volunteer. J Lipid Res 41:1790-1800.
5. Le Vuong T, Buchholz BA, Lame MW, Dueker SR. 2004. Phytochemical research using accelerator mass spectrometry. Nutr Rev 62:375-388.
6. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, et al. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317:185-191.
7. Yarchoan R, Thomas RV, Grafman J, Wichman A, Dalakas M, McAtee N, Berg G, Fischl M, Perno CF, Klecker RW, et al. 1988. Long-term administration of 3′-azido-2′,3′-dideoxythymidine to patients with AIDS-related neurological disease. Ann Neurol 23: S82-S87.
8. Blum MR, Liao SH, Good SS, de Miranda P. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 85:189-194.
9. Zimmerman TP, Mahony WB, Prus KL. 1987. 3′-Azido-3′- deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 262:5748-5754.
10. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, et al. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83:8333-8337.
11. Veal GJ, Back DJ. 1995. Metabolism of zidovudine. Gen Pharmacol 26:1469-1475.
12. 14C via accelerator mass spectrometry. Anal Chem 75:2192-2196.
13. Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS, Lee FW, Miwa GT. 2006. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 34:384-388.
14. Sandhu P, Vogel JS, Rose MJ, Ubick EA, Brunner JE, Wallace MA, Adelsberger JK, Baker MP, Henderson PT, Pearson PG, Baillie TA. 2004. Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 32:1254-1259.
15. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. 2006. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clin Pharmacol Ther 80:203-215.
16. 14C- nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 45:1198-1205.
17. Turteltaub KW, Felton JS, Gledhill BL, Vogel JS, Southon JR, Caffee MW, Finkel RC, Nelson DE, Proctor ID, Davis JC. 1990. Accelerator mass spectrometry in biomedical dosimetry: Relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci USA 87:5288-5292.
18. Frantz C, Bangerter E, Fultz K, Mayer J, Vogel C, Turteltaub K. 1995. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis 16:367-373.
19. 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197-209.
20. 14C-labeled atrazine metabolites in human urine. Anal Chem 70:3463-3469.
21. Wang LH, Chittick GE, McDowell JA. 1999. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 43:1708-1715.
22. Drew RH, Weller S, Gallis HA, Walmer KA, Bartlett JA, Blum MR. 1989. Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 33:1801-1803.